“Am I cured?”

When you wake from surgery, you want to hear your surgeon say, “We got it all.”

In many cases, surgery is all you need to be cured of early-stage lung cancer. But in at least one third of cases, the cancer comes back. Up until recently, even if your cancer was likely to return, all your doctor could offer was “watchful waiting” and hoping for the best.

That is no longer the case. Advances in molecular personalization of lung cancer care now enable your doctor to identify and treat high-risk stage I lung cancer before it comes back, with a high rate of success in preventing recurrence.

To know what to do, there is now a test that will either:

inform you that you’ll need additional treatment after surgery to lower a high risk of recurrence; or
give you peace of mind if you don’t.

What Happens After Lung Cancer Surgery

Complete cure is the goal when surgeons remove an early-stage lung tumor. For most patients in stages IA, IB and IIA, surgery does exactly that. The cancer is gone, and it won’t come back.

But for roughly one in three stage IA patients, and for an even higher proportion of patients with stages IB and IIA, microscopic cancer cells have already begun to spread undetectably to other parts of the body. These patients look like they’re cured on paper and their scans are clear, but without additional treatment, their cancer will return.

Up until now, the challenge has been knowing which group you’re in.

Until recently, there was no reliable way to know your risk of lung cancer recurrence. Doctors used tumor size and location, as well as lymph node involvement, to perform “staging,” but those tools can’t see what’s happening inside the cancer cells. The majority of patients in stages IA-IIA who needed treatment weren’t identified and eventually died as a result. Some people who didn’t need treatment were treated anyway.

RiskReveal helps determine who needs treatment and provides peace of mind to those who don’t.

The Results, in Plain Language

In a large clinical study involving patients who, just like you, had early-stage lung cancer, here’s what happened following surgery:

After surgery without treatment for high-risk patients, cancer returned within two years in more than 20% of cases.

However, in high-risk patients who had adjuvant chemotherapy:

96%

patients are diagnosed with  early-stage non-small cell lung cancer (NSCLC) each year.

98%

of early-stage patients will not survive past five years.

Compared with

79%

of high-risk patients who did not receive treatment

The chemotherapy used in this study was a well-established combination of anti-cancer drugs that, for decades, has been safely administered following lung cancer surgery. Most patients completed the full course of treatment. The risk of serious complications was low.

With adjuvant chemotherapy after surgery, nearly all high-risk patients were cancer-free at two years.

What Your Results Mean

If your result is LOW RISK

Surgery got the tumor in the lung, and the tumor likely had not spread.

You can move forward with confidence, not just hope.

Your doctor will monitor you with routine follow-up visits.

The data says you’re in the majority of patients who are cured.

If your result is HIGH RISK

Your tumor has characteristics associated with a higher likelihood of recurrence due to microscopic spread even before surgery.

With adjuvant chemotherapy after surgery, nearly all high-risk patients are cancer-free at two years.

A positive result is actionable information at the very moment your doctor has the greatest chance to cure any residual cancer.

A high-risk result means that after your successful surgery, you’ll need just one more course of treatment to be back among the lowest risk of recurrence.

What Is RiskReveal?

RiskReveal is a test of genetic activity performed on the tumor tissue that was already removed during your surgery. You don’t need any additional procedures, blood draws, or biopsies. The tissue is already available.

The test analyzes the genetic activity, also called mRNA expression, of 14 specific genes in your tumor. That pattern of genetic activity predicts, with a high degree of accuracy, whether your cancer is likely to return or not.

Two tumors that look identical under a microscope can have very different genetic activity. One has likely already spread. The other has not. RiskReveal can tell them apart. No other test has been proven to help improve the outcomes of high-risk early-stage lung cancer patients.

How to Ask for This Test

Although RiskReveal has been a rigorously validated test in clinical use for over a decade, the highest level of clinical data that demonstrate its effectiveness at guiding potentially curative therapy have only recently become available, and not every physician is familiar with that information yet. Your surgeon or oncologist may not bring it up on their own — not because it isn’t right for you, but simply because they may not have seen the data yet. You have every right to ask for the test. In fact, asking may be one of the most important things you do.

Words you can use with your doctor:

If your doctor says you’re stage I and doesn’t think further testing is needed:

Words you can use with your doctor:

If your doctor says you’re stage I and doesn’t think further testing is needed:

You are your own best advocate. The research is on your side.

What to Expect — Step by Step

Surgery is complete

RiskReveal is ordered after your surgeon removes your tumor. The tissue is already in the pathology lab and you will not need to undergo any additional procedures.

Your doctor orders the test

A simple requisition sends your tumor tissue to Razor Genomics. Nothing is required from you.

Results are available in under 10 days

Within 10 business days, your doctor receives a clear report: low-risk or high-risk.

You and your doctor make a plan

Low-risk: routine monitoring and peace of mind. High-risk: a referral to a medical oncologist to discuss chemotherapy, with confidence that treating now gives you the best possible outcome.

Insurance Coverage

Medicare Patients

No out-of-pocket cost. RiskReveal is covered for eligible Medicare beneficiaries.

Other insurance

Razor Genomics bills your insurance directly. Your insurer may cover all or part of the cost, depending on your plan.

If you have questions about coverage or financial assistance, call Razor Genomics directly:

Phone: 1-844-662-6298
Secure Fax: (949) 271-5753

Questions to Ask Your Doctor

Has my tumor tissue been sent for molecular risk testing?
Am I a candidate for the RiskReveal test?
What is my TNM stage, and what does that mean for my risk of recurrence? How would RiskReveal improve the accuracy of that risk determination?
If I’m found to be high-risk by RiskReveal, what treatment would you recommend?
How quickly do we need to make a treatment decision after surgery?
Who else will be involved in my care — a medical oncologist?

You’re Not Alone in This

Thousands of patients have been in exactly the same place you are right now — diagnosis behind them, uncertainty ahead. RiskReveal was designed for this moment. It replaces uncertainty with answers. And thousands of patients have already benefited from the test results.

Whatever your result, you’ll have the information you need to take the next right step.

Knowing is always better than wondering.

Insurance Coverage & Resources

Ready to Learn More?

Talk to your doctor about RiskReveal. If you’d like to speak with someone at Razor Genomics directly — whether about the test, insurance coverage, or what to expect — we’re here.

Billing: 1-844-662-6298

Secure Fax: (949) 271-5753

Robert McKenna, MD

Thoracic Surgeon, John Wayne Cancer Institute 

I think that RiskReveal is practice-changing and very important for discussions that we have with patients. I like giving patients enough information about their situation, and the pros and cons of additional treatment after their operation, so they’re loaded with the information to help them decide if they want adjuvant treatment.

Alejandro Calvo, MD

Medical Oncologist, Kettering Cancer Center 

In medical oncology, data is very important, especially reliable data. The prospective randomized validation of RiskReveal gives me confidence to use chemotherapy in the subset of patients that need it. And it allows the patients also to feel more confident taking some risks by knowing the benefit they obtain.

Edgardo Santos, MD, FACP

Florida Precision Oncology

“The integration of testing for chemotherapy selection by RiskReveal will enable oncologists to optimize treatment post-surgery. In my opinion, this test closes the few remaining gaps that we currently face in deciding adjuvant therapy for early-stage adenocarcinoma of the lung. With these results, I feel confident initiating chemotherapy for RiskReveal high-risk patients I see in my practice.”

Surgeons

Medical Oncologists

Pathologists

Nurse Navigators